Eli Lilly's GLP-1 drugs fuel massive growth, with potential $60bn+ annual revenue. Check out why I remain bullish long term ...

Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

Shares of Eli Lilly (LLY) are testing a resistance level. If they can break through this resistance, a large more higher may follow.

Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway.

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

There's nothing like a successful clinical trial of a high-potential medicine to blast a pharmaceutical company 's stock price higher. That was the dynamic behind Eli Lilly 's (NYSE: LLY) nearly 6% ...

Eli Lilly and Company drives growth with innovative diabetes and obesity drugs, expanding portfolios, and R&D strength. Click for more on LLY stock prospects.

Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...

The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...